Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5844102 | Pharmacology & Therapeutics | 2015 | 14 Pages |
Abstract
We discuss lessons learned from recent mechanistic studies of selective glucocorticoid receptor modulators. This is approached by analyzing recent experimental insights in comparison with knowledge obtained using mutant GR research, thus clarifying the current view on the SEGRAM field. These insights also contribute to our understanding of the processes controlling glucocorticoid-mediated side effects as well as glucocorticoid resistance. Our perspective on non-steroidal SEGRAs and SEGRMs considers remaining opportunities to address research gaps in order to harness the potential for more safe and effective glucocorticoid receptor therapies.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Nora Sundahl, Jolien Bridelance, Claude Libert, Karolien De Bosscher, Ilse M. Beck,